Losartan & Emotional Memory

Status Completed

Clinical Trial Summary

This study explores the effects of single-dose losartan (50mg) versus identical placebo capsule on emotional memory and learning in healthy volunteers.

Clinical Trial Description

The commonly prescribed antihypertensive drug losartan (brand name: Cozaar; UK licensed for 20 years) targets the renin-angiotensin system - a hormone system regulating blood pressure - by acting as an angiotensin receptor antagonist. In particular, the drug prevents a docking of the protein angiotensin IV to AT1 receptors, which leads to a dilation if vessels and a reduction in blood pressure. However, the increase in free angiotensin IV has also been associated with an increase in synaptic plasticity, the cellular mechanism involved in learning and memory. As such, losartan appears to have cognition-enhancing properties, in a way that a single dose of 50mg improves prospective memory in healthy humans. However, preliminary pre-clinical results also suggest that a single injection of the drug improves fear extinction in rodents, which is the equivalent to human cognitive-behavioural therapy for anxiety disorders. Furthermore, compared to other antihypertensive drugs, regular losartan treatment appears to prevent the development of post-traumatic stress disorder symptoms following trauma exposition. Such results suggest that the renin-angiotensin system plays a key role in the development and extinction of anxiety, and that adding losartan to cognitive-behavioural therapy for anxiety in humans might have synergistic effects. However, it remains to be clarified what the basic effects of this drug on emotional information processing in humans are to identify mechanisms by which it may improve psychological treatments.

In this study, the key neuropsychological effects of probing the renin-angiotensin system on emotional information processing and learning will be investigated. In a double-blind, randomised between-groups design, 54 healthy volunteers will be randomised to a group receiving a single dose of losartan (50mg) versus placebo. When peak plasma levels are reached, participants will work on a battery of behavioural measures of emotional information processing and learning.

The results from this study will help understand how the renin-angiotensin system affects emotional information processing and learning, and they will help establish a battery of tasks that sensitively respond to such manipulations. Such information will ultimately lead to the development of losartan and similar agents for the more effective and more compact treatment of anxiety disorders. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03763409
Study type	Interventional
Source	University of Oxford
Contact
Status	Completed
Phase	N/A
Start date	March 1, 2018
Completion date	September 28, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01007682` - Intrusive Reexperiencing: The Role of Working Memory Capacity and Thought Suppression	N/A
Completed	`NCT04330677` - Dissecting the Role of Estradiol in Mediating Gender-specific Anxiolytic and Prosocial Effects of Oxytocin	Phase 1
Active, not recruiting	`NCT04392908` - Communication Memory of Cancer Diagnosis Within the Pediatric Triangle
Recruiting	`NCT04694534` - Remediation Program Via a "Serious Game" for the Cognitive Functions of Multiple Sclerosis Patients	N/A
Completed	`NCT01159652` - Hypnotic Medications and Memory: Effect of Drug Exposure During the Night	Phase 4
Recruiting	`NCT04598945` - Acquisition and Retention of Motor Memories in Adults and Typically Developing Children	N/A
Terminated	`NCT04021797` - Autonomic Mechanisms of Sleep-dependent Memory Consolidation	N/A
Not yet recruiting	`NCT04103463` - Interactive Stepping Exercise on Memory	N/A
Completed	`NCT04025255` - The Memory and Cognitive Performance Study	N/A
Recruiting	`NCT06351098` - Longitudinal Investigation of Sleep, Memory, and Brain Development Across the Nap Transition	Early Phase 1
Completed	`NCT06047899` - Influence of Luteolin for Two Weeks on Memory in Healthy Subjects	N/A
Recruiting	`NCT04402294` - Individualized Closed Loop TMS for Working Memory Enhancement	N/A
Completed	`NCT01126229` - Resveratrol for Improved Performance in the Elderly	Phase 1
Completed	`NCT00913640` - Prospective Memory in Parkinson's Disease
Completed	`NCT03974399` - BDNF Levels After Bacopa	N/A
Completed	`NCT01143194` - A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Effects of Three Doses of the Dietary Supplement oréVida™ on Alertness, Attention and Concentration in Healthy Men and Women	Phase 1
Completed	`NCT00454454` - Virtual Reality Helmet to Test for Problems With Memory	N/A
Completed	`NCT00584324` - Depth of Anesthesia on Implicit Memory	N/A
Completed	`NCT06074172` - The Effect of Cannabidiol in Learning and Memory of Adults	Phase 2
Completed	`NCT05907707` - Effects of Gamma-tACS on Memory and Sleep	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Losartan and Emotional Memory

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms